Knight Therapeutics Inc.

Good morning, ladies and gentlemen. My name is Taryn, and I will be your operator today. Welcome to Knight Therapeutics' fourth quarter and year-end 2022 results conference call. Before turning the call over to Samara Sakiya, President and CEO of Knight, listeners are reminded that portions of today's discussion may, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but conscience that these assumptions regarding the future events, many of which are beyond the control of the company and its subsidiaries, may ultimately prove to be incorrect. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether a result of new information, future events, except as required by law. We would also like to remind you, questions during today's call will be taken from analysts only. Should there be any further questions, please contact Knight's Investor Relations Department via email to info at knighttx.com or via phone at 514-484-4483. I would like to remind everyone that this call is being recorded today, March 23, 2023. and would now like to turn the meeting over to your host for today's call, Samara Zakiya. Please go ahead, Ms. Zakiya.

Thank you, Taryn. Good morning, everyone, and welcome to Knight Therapeutics' fourth quarter and URAN 22 conference call. I am joined on today's call with Amal Khoury, our Chief Business Officer, Arvind Uchana, our Chief Financial Officer, and Jeff Martins, our Global VP Commercial. I'm excited to announce that we delivered another great year in 2022 and reported record revenues of over $290 million, a growth of 21% over last year, as well as record adjusted EBITDA of over $54 million, an increase of 42% over last year. This growth was generated by the full-year effect of Exelon, the impact of our recent launches in Colombia, as well as continued growth from our key promoted products. We have also executed on all aspects of our portfolio strategy. We in-licensed at Kinzeo a product with existing sales in our key markets and further expanded our innovative pipeline with the in-licensing of Fosamatinib from Rigel. We also added three products to our branded generic pipeline, which include the rights to the two largest markets in LATAM, Brazil and Mexico. On the regulatory front, we continued to advance the pipeline and submitted tefacitamab, or Minjuvi, in Brazil, Colombia, and Argentina, as well as two branded generic products in each of Chile and Colombia, and obtained the regulatory approval of Palbosil in Argentina. In addition to delivering record results and advancing our pipeline, 2022 was very productive as we completed the integration of GBT and fully onboarded Exelon and Ekinzeo. Turning now to the NCID. During the year, we purchased approximately 5.6 million common shares for aggregate cash consideration of over $30 million. Subsequent to the quarter, Knight has purchased an additional 1.3 million common shares for aggregate cash consideration of $6.5 million. The average purchase price of the shares purchased through the NCIB launched in July 22 was $5.31 per share. I'm now going to turn the call over to Jeff to provide more details on our product results.

Thank you, Samira. In 2022, as Samira mentioned, we have delivered record revenues of over $290 million, an increase of over $48 million on a constant currency basis or 20% over prior year. We grew across all of our therapeutic areas due to the increasing market penetration of our new launches, as well as the full year acquisition effect of Exelon. Now moving to our oncology hematology portfolio. During the year revenues, excluding hyperinflation, were $105.5 million, a growth of $16.4 million, or 18% versus the same period last year. This includes the contribution from our key promoted brands, including new launches of Limevima, Palavant, and Rembrandt in Colombia in the first quarter of 2022. The growth of our promoted products in all territories and the addition of Akenzeo in Brazil and Canada. This increase was partially offset by a decline in sales of certain branded generic products due to their life cycle and entrance of new generic competitors. As for our infectious disease portfolio, we delivered revenues of $116.5 million, excluding hyperinflation. Our portfolio grew by $29 million due to an increase in patient treatments as our markets reduced COVID-19 restrictions. Growth of our key promoted products and a one-time sales contract with the Ministry of Health in Brazil for Amazon. We recorded a $7.5 million in the quarter which represents 40% of the full value of the contract, and we expect to deliver the balance in the first half of 2023. This growth is offset by an estimated $14.2 million due to lower COVID-related demand for certain of our infectious disease products that were used to treat invasive fungal infections associated with COVID-19 and the planned transition and termination of the Gilead Agreement effective July 1, 2022. Now moving to our other specialty portfolio. During the year, revenues excluding hyperinflation were $69.8 million, an increase of $21.3 million compared to prior year. This increase is mainly due to the full year effective Exelon and the change in accounting treatment from net profit transfer to recognition of net revenues and related cost of sales. I will now turn the call over to Arvind to provide an update on our financial results.